Continuous Glucose Monitoring– tag –
-
Abbott’s Libre Duo 10-Day System Receives FDA Authorization as First Wearable Continuous Glucose-Ketone Monitor in U.S.
Diabetes Education Services USA Overview Abbott has secured FDA authorization for its Libre Duo 10 Day Continuous Dual Glucose-Ketone Monitoring System, making it the first wearable device in the U.S. and globally to continuously monitor... -
Abbott Secures Sweeping Injunction Against SiBio’s GS3-R CGM System at Unified Patent Court, Intensifying IP Disputes in Medtech
Facebook USA Overview Abbott Diabetes Care has secured a broad preliminary injunction from the Unified Patent Court (UPC) against SiBio's GS3-R continuous glucose monitoring (CGM) system, effective September 10, 2026. This significant ru... -
FDA Marks New Era in Diabetes Care with First Dual Glucose-Ketone Wearable and OTC Pediatric CGM
FDA News / Health Technology News USA Overview The U.S. FDA has ushered in a new chapter for diabetes technology, authorizing Abbott's Libre Duo as the first wearable device for continuous dual monitoring of glucose and ketones, and clea... -
Self-Powered Paper Patch Developed by Binghamton University Non-Invasively Monitors Sweat Glucose During Exercise
Binghamton News USA Overview Researchers at Binghamton University have developed a self-powered, disposable paper patch capable of non-invasively monitoring glucose levels in sweat during exercise. This innovative wearable sensor integra... -
Dexcom Gains FDA Clearance for G7 15-Day CGM and Smart Basal, Joins TEMPO Pilot Program
Simply Wall St USA Overview Dexcom has secured FDA clearance for its Dexcom G7 15-Day continuous glucose monitoring (CGM) system, extending wear time to 15.5 days for all types of adult diabetes patients. Simultaneously, Dexcom Smart Bas... -
FDA Reiterates No Non-Invasive Glucose Monitors Approved; Tech Giants Pursue Inferential Wearables
Medium (Sahha AI Blog) USA Overview As of September 2026, the FDA has reiterated that no non-invasive glucose monitoring devices are approved, cautioning consumers against smartwatches or rings claiming to measure blood sugar without ski... -
Abbott’s Libre Duo 10 Day System Receives FDA De Novo Clearance as First Integrated Continuous Glucose-Ketone Monitor
Pharmacy Times USA Overview Abbott's Libre Duo 10 Day system has received FDA De Novo clearance, becoming the first integrated continuous glucose-ketone monitoring (iCGK) system in the U.S. and the world's first wearable device to track ... -
Porous Microneedles Achieve High-Sensitivity Detection of Glucose in Rat Skin Interstitial Fluid
ResearchGate (Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy) International Overview Research published on ResearchGate reports a new method using porous microneedles for qualitative and quantitative detection of glu... -
MDPI Review Maps Biosensors’ Evolution to Integrated Systems for Molecular Diagnostics and Longitudinal Clinical Monitoring
MDPI (Biosensors Journal) International Overview A new review from MDPI details the transformation of biosensors from simple analytical detectors into integrated systems crucial for molecular diagnostics, longitudinal monitoring, dynamic... -
TechRadar Hails ‘Diabetes Breakthrough’: FDA Approves Abbott’s World’s First Dual-Sensor CGM
TechRadar UK Overview TechRadar reported the FDA's approval of Abbott's Libre Duo 10 Day as a 'diabetes breakthrough.' This is the world's first dual-sensor Continuous Glucose Monitoring (CGM) system capable of simultaneously tracking bo...
